MCC950 treatment effectively attenuated the inflammatory symptoms of NLRP3-related diseases, including experimental autoimmune meningitis and cryopyrin-associated periodic syndrome (CAPS) (Coll et al., 2015). This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.